Johnson & Johnson $JNJ Position Lowered by Cornerstone Advisors LLC

Cornerstone Advisors LLC lowered its position in shares of Johnson & Johnson (NYSE:JNJ) by 6.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 157,591 shares of the company’s stock after selling 11,195 shares during the quarter. Johnson & Johnson comprises approximately 1.4% of Cornerstone Advisors LLC’s portfolio, making the stock its 14th biggest position. Cornerstone Advisors LLC’s holdings in Johnson & Johnson were worth $41,721,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the stock. CKW Financial Group boosted its holdings in Johnson & Johnson by 0.9% in the third quarter. CKW Financial Group now owns 4,269 shares of the company’s stock worth $1,104,000 after acquiring an additional 37 shares in the last quarter. Silver Coast Investments LLC raised its holdings in Johnson & Johnson by 3.8% in the 2nd quarter. Silver Coast Investments LLC now owns 1,066 shares of the company’s stock worth $271,000 after acquiring an additional 39 shares during the last quarter. Townsend Asset Management Corp NC ADV raised its holdings in Johnson & Johnson by 0.6% in the 2nd quarter. Townsend Asset Management Corp NC ADV now owns 6,418 shares of the company’s stock worth $1,630,000 after acquiring an additional 39 shares during the last quarter. Triumph Capital Management lifted its position in Johnson & Johnson by 1.6% in the 2nd quarter. Triumph Capital Management now owns 2,531 shares of the company’s stock valued at $643,000 after acquiring an additional 39 shares in the last quarter. Finally, Kwmg LLC lifted its position in Johnson & Johnson by 1.7% in the 3rd quarter. Kwmg LLC now owns 2,383 shares of the company’s stock valued at $631,000 after acquiring an additional 39 shares in the last quarter. 69.55% of the stock is owned by institutional investors.

Insider Transactions at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 15,000 shares of the company’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the completion of the sale, the executive vice president owned 194,451 shares in the company, valued at approximately $51,210,615.36. This represents a 7.16% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Timothy Schmid sold 33,597 shares of the stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total value of $9,230,439.78. Following the completion of the transaction, the executive vice president directly owned 25,447 shares in the company, valued at approximately $6,991,308.78. This represents a 56.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 61,669 shares of company stock worth $16,898,386 in the last ninety days. Insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have commented on JNJ shares. Bank of America reissued a “neutral” rating and issued a $278.00 target price on shares of Johnson & Johnson in a report on Tuesday, September 29th. Johnson Rice downgraded Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Wednesday, October 21st. Morgan Stanley lowered their price target on Johnson & Johnson from $294.00 to $292.00 and set an “overweight” rating on the stock in a report on Thursday, October 15th. Wells Fargo & Company increased their price objective on Johnson & Johnson from $275.00 to $287.00 and gave the company an “overweight” rating in a research report on Friday, October 16th. Finally, Weiss Ratings downgraded Johnson & Johnson from a “buy (b+)” rating to a “buy (b-)” rating in a report on Friday, October 23rd. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have issued a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $275.92.

Johnson & Johnson Stock Up 0.8%

Shares of Johnson & Johnson stock opened at $285.78 on Friday. The company has a market cap of $687.95 billion, a price-to-earnings ratio of 43.30, a price-to-earnings-growth ratio of 2.80 and a beta of 0.22. The company’s 50 day moving average is $266.97 and its 200 day moving average is $249.85. Johnson & Johnson has a twelve month low of $193.55 and a twelve month high of $288.11. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.53 by $0.06. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The company had revenue of $25.40 billion for the quarter, compared to analysts’ expectations of $25.38 billion. During the same quarter last year, the company posted $2.80 earnings per share. The firm’s quarterly revenue was up 5.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. Research analysts anticipate that Johnson & Johnson will post 11.12 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be paid a $1.34 dividend. This represents a $5.36 dividend on an annualized basis and a dividend yield of 1.9%. The ex-dividend date is Tuesday, November 24th. Johnson & Johnson’s dividend payout ratio (DPR) is 81.21%.

Recent Johnson & Johnson Headlines

These are some of the JNJ headlines that stood out recently:

• Positive Sentiment: A Johnson & Johnson prostate-cancer drug combination is advancing into Phase 3, a meaningful clinical milestone that could strengthen the company’s oncology pipeline, although trial and commercial outcomes remain uncertain. Johnson & Johnson stock advances as prostate drug combo enters Phase 3
• Positive Sentiment: J&J is backing Francis Medical as it advances a water-vapor prostate-cancer treatment device toward FDA premarket approval. The investment expands its reach in minimally invasive oncology treatment. J&J leads Francis Medical investment to fund prostate cancer device
• Neutral Sentiment: J&J also led a $100 million funding round for Delix Therapeutics’ depression-drug development. This broadens its exposure to emerging psychiatric treatments, but clinical-stage programs carry substantial execution risk. Johnson & Johnson Backs New Cancer Device And Leads $100 Million Depression Bet

About Johnson & Johnson

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.